← Leaderboards
Che-Chung Tsai
University Of Washington
$4,061,556
Attributed
$4,061,556
Total exposure
25
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $844.3K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,061,556 · 25
By mechanism
P51$4,005,684 · 24
N01$55,872 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Dorothy L Patton$29,988,859
- Kim A. Woodrow$13,186,657
- David A. Eschenbach$4,842,107
- Raymond Scott McClelland$25,618,064
- Alison L Drake$4,277,030
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusInflammationCommunicable DiseasesClinical ResearchLymphatic SystemMammaliaImmunologyAidsClinical TrialsMacacaOrphan Disease /DrugDrug Adverse EffectCardiovascular SystemUrinary TractAnimal ColonyInstitutionComputer Retrieval Of Information On Scientific Projects DatabasePrimatesResearch PersonnelGrantFundingSourceBaseResources
Grant awards (27)
Primate Models to Evaluate HIV Prevention & Therapeutic Strategies$55,872
N01 · FY2011 · AI · contact PI
VAGINAL TRANSMISSION OF A PATHOGENIC RT-SHIVTC IN CYNOMOLGUS MACAQUES$232,629
P51 · FY2010 · RR · contact PI
PRIMATE MODELS FOR HIV PREVENTION AND THERAPEUTIC STRATEGIES$232,629
P51 · FY2010 · RR · contact PI
MACACA FASCICULARIS SUSCEPTIBILITY TO RT-SHIV FOLLOWING INTRAVAGINAL INOCULATION$331,394
P51 · FY2009 · RR · contact PI
AIDS THERAPIES$422,135
P51 · FY2008 · RR · contact PI
AIDS THERAPIES II$422,135
P51 · FY2008 · RR · contact PI
INDUCTION OF CHRONIC SIVMNE INFECTION IN MACAQUES$177,333
P51 · FY2005 · RR
CLINICAL PHARMACOKINETICS AND/OR TOXICITY STUDIES OF ANTI-HIV-AGENTS FOR MACAQUE$177,333
P51 · FY2005 · RR
IN VIVO ADAPTATION OF SHIVSF162P3 IN PIGTAILED MACAQUES$175,831
P51 · FY2005 · RR
SCREENING FOR ANTIVIRAL CONTRACT ANIMALS$175,831
P51 · FY2005 · RR
IN VIVO ADAPTATION OF SHIVSF162P3 IN PIGTAILED MACAQUES$161,398
P51 · FY2004 · RR
SCREENING FOR ANTIVIRAL CONTRACT ANIMALS$161,398
P51 · FY2004 · RR
SPL7013 GELS AS MICROBICIDE INHIBIT VAGINAL TRANSMISSION OF SHIV89.6P IN MACAQUE$161,398
P51 · FY2004 · RR
CYANOVIRIN-N AS A MICROBICIDE FOR SHIV89.6P TRANSMISSION$161,398
P51 · FY2004 · RR
CYANOVIRIN-N A MICROBICIDE PREVENTS RECTAL TRANSMISSION$161,398
P51 · FY2004 · RR
SCREENING FOR ANTI-VIRAL CONTRACT ANIMALS$189,414
P51 · FY2003 · RR
IN VIVO TITRATION OF UNCLONED SIVMNE VIRUS STOCK$0
P51 · FY2001 · RR
SCREENING MACAQUES PRIOR TO TESTING OF ANTI VIRAL AGENTS$0
P51 · FY2001 · RR
TITRATION OF UNCLONED SIVPBJ14 VIRUS STOCK$0
P51 · FY2001 · RR
PHARMACOKINETICS OF 14C LABELED ANTIRETROVIRAL NUCLEOSIDE$0
P51 · FY2001 · RR
PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL AGENTS$0
P51 · FY2001 · RR
AIDS THERAPIES$0
P51 · FY2001 · RR
IN VIVO TITRATION &TRANSMISSION OF SHIV89 6P STOCK$132,406
P51 · FY2000 · RR
PHARMACOKINETICS OF INDINAVIR, PROTEASE INHIBITOR OF HIV 1$132,406
P51 · FY2000 · RR
ANTIRETROVIRAL AGENTS IN MACAQUE MODELS: SIV$132,406
P51 · FY2000 · RR
EVALUATIING AIDS THERAPIES IN MACAQUE MODELS SCREENING SUBJECTS$132,406
P51 · FY2000 · RR
IN VIVO TITRATION &TRANSMISSION OF SIVMNE STOCK$132,406
P51 · FY2000 · RR